Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 3,266 shares at $54.84 ($179K) on 2025-06-18, disclosed to the SEC on 2025-06-20.
Open-market sale of $179k AKRO by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.84 | 1,633 | $90K | 50.0% |
| 2 | $54.84 | 1,633 | $90K | 50.0% |
| Total | $54.84 avg | 3,266 | $179K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |
| AKRO | SELL | 2025-05-19 | $786K | — | Filing → |